Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Journal of Experimental Hematology ; (6): 820-826, 2019.
Article in Chinese | WPRIM | ID: wpr-771878

ABSTRACT

OBJECTIVE@#To investigate the expression of miR-101 and EZH2 in patients with mantle cell lymphoma(MCL) and to analyze its correlation with clinical prognosis of MCL patients.@*METHODS@#RQ-PCR and S-P immunohistochemistry were used to detect the expressions of miR-101 and EZH2 in tissue of MCL patients. CCK-8 was used to assay the effect of miR-100 minics on the proliferation of Jeko-1 and Mino cells; the flow cytometry with Annexin V/PI double staining was used to assay the apoptosis; Western blot was used to assay the effect of miR-101 minics on the expression of EZH2 protein in Jeko-1 and Mino cells.@*RESULTS@#Compared with control group, miR-101 lowly expressed, and EZH2 protein highly expressed in MCL group, with very statistically significant difference(P<0.01).There was negative correlation between miR-101 and EZH2 expression(r=-0.638,P<0.05). The expression of miR-101 and EZH2 significantly correlated with B symptoms, International Prognostic Index(IPI) and Ann Arbor stage, respectively. Survival analysis showed that the overall survival(OS) rate of patients with low expression of miR-101 were significantly lower than that of patients with high miR-101 expression (P=0.0014), the OS rate of patients with EZH2 high expression were significantly lower than that of patients with EZH2 low expression (P=0.0093). The miR-100 minics could inhibit the proliferation of Jeko-1 and Mino cells, and increase the apoptotic rate. The expression of EZH2 protein was markedly suppressed by the miR-100 minics.@*CONCLUSION@#The expression of miR-101 and EZH2 is different in MCL patients with different clinical stage and prognosis. The miR-101 can inhibit the cell proliferation and induce cell apoptosis of mantle cell lymphoma by targeting EZH2.


Subject(s)
Humans , Apoptosis , Cell Proliferation , Enhancer of Zeste Homolog 2 Protein , Genetics , Lymphoma, Mantle-Cell , Genetics , MicroRNAs , Genetics , Prognosis
2.
Chinese Journal of Pathology ; (12): 730-735, 2007.
Article in Chinese | WPRIM | ID: wpr-350027

ABSTRACT

<p><b>OBJECTIVE</b>To study the clinicopathologic features and prognostic factors of Chinese patients with mantle cell lymphoma.</p><p><b>METHODS</b>One hundred and two cases of mantle cell lymphoma occurring in Chinese patients were studied by light microscopy and immunohistochemistry. The follow-up information was also analyzed. The cases were classified as mantle zone, nodular or diffuse patterns and as typical or blastoid variants. Age, Ann-Arbor staging, B symptoms, hematologic parameters, histologic variants, mitotic index and immunophenotype were assessed for possible prognostic implication.</p><p><b>RESULTS</b>The median age of the patients was 59 years (range: 30 to 79 years) and the male-to-female ratio was 2.92:1. Seventy-one patients (87.65%) presented with advanced stage disease (Ann Arbor stage III to IV). B symptoms were present in 45.45% of patients. The commonest site of involvement was lymph node (100%). The other involved sites included bone marrow (64.44%), spleen (63.16%), Waldeyer's ring (31.25%), peripheral blood (29.41%), liver (22.64%) and gastrointestinal tract (14.71%). All cases expressed B-cell markers but were negative for T-cell marker. Majority of cases were positive for cyclin D1 (94.12%) and CD5 (71.43%). Blastoid variant accounted for 24.51% of cases. Amongst the 68 cases with follow-up data available, the median survival was 10 months. Parameters associated with shorter survival included diffuse pattern, blastoid variant, high mitotic index, high proliferative activity and presence of bone marrow involvement.</p><p><b>CONCLUSIONS</b>The clinicopathologic features and prognostic factors of mantle cell lymphoma occurring in Chinese are similar to those in Caucasians. Diffuse pattern, blastoid variant, high mitotic index, high proliferative activity and involvement of bone marrow indicate poor prognosis.</p>


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Antigens, CD20 , Metabolism , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , CD5 Antigens , Metabolism , CD79 Antigens , Metabolism , Combined Modality Therapy , Cyclin D1 , Metabolism , Cyclophosphamide , Therapeutic Uses , Doxorubicin , Therapeutic Uses , Follow-Up Studies , Lymphoma, Mantle-Cell , Metabolism , Pathology , Therapeutics , Prednisone , Therapeutic Uses , Prognosis , Vincristine , Therapeutic Uses
SELECTION OF CITATIONS
SEARCH DETAIL